We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Leonard Schleifer supportive of FTC’s lawsuit against takeover of Horizon Therapeutics
Eli Lilly, Amgen, Pfizer and Regeneron follow Novo Nordisk into obesity treatments worth billions
FDA says treatments from Regeneron and Eli Lilly ‘highly unlikely’ to work against Omicron strain
Biotech says some antibody therapies may need to be modified to tackle new coronavirus variant
Excessive boosterism and US partisan divisions risk undermining a limited but effective therapy
Suggestion ex-secretary of state would have benefited from treatment dismissed as ‘highly speculative’
Supplies of Covid-19 drugs are running short, especially in states with low vaccination rates
US start-up co-founded by Nobel laureate marks breakthrough over therapies restricted to external cells
Clinical trial shows the therapy helps those who fail to make their own antibodies against coronavirus
Company to ask FDA to expand use of antibody cocktail as preventive treatment
The FDA issues emergency use authorisation for Regeneron’s antibody treatment
Company says it still needs to ‘button down’ plans to reach those who could benefit most from antibody treatment
Drug hailed as coronavirus ‘cure’ by Donald Trump will still be studied in mild-to-moderate cases
Early signs are promising but there will be limits on how much the drug companies can charge
President’s championing of novel therapy thrusts biotech group into uncomfortable spotlight
Administration has tried to restrict practice of using aborted human tissue for scientific studies
Shares in manufacturers rise after US president praises experimental therapy
President given experimental treatments for Covid-19 at Walter Reed facility
Stock sale by French drugmaker will be used to develop new drugs and to fuel acquisitions
Extra firepower will expand French pharmaceutical company’s options
Chief executive Paul Hudson says proceeds will go to scientific research and potentially acquisitions
Groups join effort to repurpose existing remedies in fight against global pandemic
Netflix, Clorox and drugmakers weather market rout sparked by coronavirus
Drugmakers lower cost of anti-cholesterol drug amid slow take-up and political pressure
Sales of Praluent have been hurt by the campaign to limit US pharmaceuticals costs
International Edition
